172 related articles for article (PubMed ID: 28706011)
1. Increased IFNγ
Li X; Zhang Y; Chen M; Mei Q; Liu Y; Feng K; Jia H; Dong L; Shi L; Liu L; Nie J; Han W
Clin Cancer Res; 2017 Oct; 23(20):6031-6043. PubMed ID: 28706011
[No Abstract] [Full Text] [Related]
2. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
3. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
[TBL] [Abstract][Full Text] [Related]
4. DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.
Nie J; Zhang Y; Li X; Chen M; Liu C; Han W
Oncotarget; 2016 Jun; 7(25):37882-37892. PubMed ID: 27191266
[TBL] [Abstract][Full Text] [Related]
5. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.
Dubovsky JA; Powers JJ; Gao Y; Mariusso LF; Sotomayor EM; Pinilla-Ibarz JA
Leuk Res; 2011 Sep; 35(9):1193-9. PubMed ID: 21377729
[TBL] [Abstract][Full Text] [Related]
7. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.
Nie J; Liu L; Li X; Han W
Cancer Lett; 2014 Nov; 354(1):12-20. PubMed ID: 25130173
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature.
Serravalle S; Bertuccio SN; Astolfi A; Melchionda F; Pession A
Biomed Res Int; 2016; 2016():1985750. PubMed ID: 28003999
[TBL] [Abstract][Full Text] [Related]
9. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
10. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
Wang Y; Tong C; Dai H; Wu Z; Han X; Guo Y; Chen D; Wei J; Ti D; Liu Z; Mei Q; Li X; Dong L; Nie J; Zhang Y; Han W
Nat Commun; 2021 Jan; 12(1):409. PubMed ID: 33462245
[TBL] [Abstract][Full Text] [Related]
11. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
12. Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497.
Liu L; Chen L; Wu X; Li X; Song Y; Mei Q; Nie J; Han W
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1431-9. PubMed ID: 27075177
[TBL] [Abstract][Full Text] [Related]
13. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells
Wang Z; Wang Z; Li S; Li B; Sun L; Li H; Lin P; Wang S; Teng W; Zhou X; Ye Z
Front Immunol; 2018; 9():1239. PubMed ID: 29910819
[TBL] [Abstract][Full Text] [Related]
14. Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo.
Zhou JH; Yao YS; Wang LX; Wang J; Li YH; Jiang MM; Zhou MH; Gao XN; Li RS; Wang LL; Yu L
Chin Med J (Engl); 2013 Dec; 126(23):4552-6. PubMed ID: 24286424
[TBL] [Abstract][Full Text] [Related]
15. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
17. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.
Lund P; Kotova I; Kedinger V; Khanwalkar H; Voltz E; Hahn WC; Gronemeyer H
Mol Cancer Ther; 2011 Sep; 10(9):1611-23. PubMed ID: 21697397
[TBL] [Abstract][Full Text] [Related]
18. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Wang L; Amoozgar Z; Huang J; Saleh MH; Xing D; Orsulic S; Goldberg MS
Cancer Immunol Res; 2015 Sep; 3(9):1030-41. PubMed ID: 26056145
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ
Li X; Dong L; Liu J; Wang C; Zhang Y; Mei Q; Han W; Xie P; Nie J
Front Cell Dev Biol; 2021; 9():647713. PubMed ID: 33791306
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]